ENRIQUE
BENGOECHEA NERECAN
![Foto de ENRIQUE](/img/nophoto.png)
![Foto de Hospital Universitario 12 de Octubre](/img/noimage_org.png)
Hospital Universitario 12 de Octubre
Madrid, EspañaPublications in collaboration with researchers from Hospital Universitario 12 de Octubre (13)
2019
-
Correction: Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role (Leukemia, (2018), 32, 11, (2427-2434), 10.1038/s41375-018-0072-6)
Leukemia
-
Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature
Blood Cancer Journal, Vol. 9, Núm. 4
2018
-
Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role
Leukemia, Vol. 32, Núm. 11, pp. 2427-2434
-
Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials
PLoS ONE, Vol. 13, Núm. 9
2016
-
Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials
Annals of Hematology, Vol. 95, Núm. 12, pp. 2033-2041
-
Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM
Blood, Vol. 127, Núm. 4, pp. 420-425
2015
-
Critical analysis of the stringent complete response in multiple myeloma: Contribution of sFLC and bone marrow clonality
Blood, Vol. 126, Núm. 7, pp. 858-862
2014
-
GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: Do we still need alkylators?
Blood, Vol. 124, Núm. 12, pp. 1887-1893
2012
-
Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients
Leukemia, Vol. 26, Núm. 8, pp. 1862-1869
-
Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial
Blood, Vol. 120, Núm. 13, pp. 2581-2588
2011
-
Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma
Journal of Clinical Oncology, Vol. 29, Núm. 12, pp. 1627-1633
-
Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance
Blood, Vol. 118, Núm. 17, pp. 4547-4553
2010
-
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: A randomised trial
The Lancet Oncology, Vol. 11, Núm. 10, pp. 934-941